/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

S

Stephen Chia

BC Cancer Agency(CA)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

463

Papers

23.6K

Citations

67

h-index

181

i10-index

Stephen Chia is an academic researcher from BC Cancer Agency. The author has contributed to research in topics: Breast Cancer Treatment Studies & Advanced Breast Cancer Therapies & HER2/EGFR in Cancer Research. The author has an h-index of 67, co-authored 394 publications.

ORCID: 0000-0001-7070-4386

Research Topics

Breast Cancer Treatment Studies Advanced Breast Cancer Therapies HER2/EGFR in Cancer Research Cancer Treatment and Pharmacology Cancer Genomics and Diagnostics

Papers by this author

works

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

2009 · JNCI Journal of the National Cancer Institute · 2,199 citations

https://doi.org/10.1093/jnci/djp082

Maggie C.U. Cheang Stephen Chia David Voduc Dongxia Gao

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

2016 · The Lancet Oncology · 551 citations

https://doi.org/10.1016/s1470-2045(15)00551-3

Arlene Chan Suzette Delaloge Frankie A. Holmes Beverly Moy

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

2017 · The Lancet Oncology · 532 citations

https://doi.org/10.1016/s1470-2045(17)30376-5

José Baselga Seock‐Ah Im Hiroji Iwata Javier Cortés

Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes

2016 · JAMA Oncology · 369 citations

https://doi.org/10.1001/jamaoncol.2015.6113

Kristine Broglio Melanie Quintana Margaret Foster Melissa Olinger

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

2021 · The Lancet Oncology · 340 citations

https://doi.org/10.1016/s1470-2045(21)00034-6

Hope S. Rugo Florence Lerebours Eva Ciruelos Pamela Drullinsky

Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers

2008 · Journal of Clinical Oncology · 299 citations

https://doi.org/10.1200/jco.2007.15.8659

Stephen Chia B. Norris Caroline Speers Maggie C.U. Cheang

Research topics

topics

Breast Cancer Treatment Studies

Advanced Breast Cancer Therapies

HER2/EGFR in Cancer Research

Cancer Treatment and Pharmacology

Cancer Genomics and Diagnostics

Chat about Author

Papers

Chat

Click to start Chat